CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
6 research outputs found
Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Author
Aileen Cohen
Brad S. Kahl
+7 more
Carol Marimpietri
Constantine Si Lun Tam
Jane Huang
Jennifer R. Brown
Paolo Ghia
Peter Hillmen
Tadeusz Robak
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
Author
Andrew Warwick Roberts
Christiane Pott
+10 more
Constantine Si Lun Tam
David A. Westerman
Glenda Burke
John Francis Seymour
Mark A Dawson
Martin H. Dreyling
Mary Ann Anderson
Rodney J Hicks
Sarah Kamel
Sarah-Jane Dawson
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.
Author
Brenda Jeglinski
Bryone J. Kuss
+13 more
Carol Moreno
Constantine Si Lun Tam
James H. Essell
Julio Delgado
Marco Montillo
Matthew Steven Davids
Ngocdiep T. Le
Nicole Lamanna
Paolo Ghia
Peter Hillmen
Stephan Stilgenbauer
Ulrich Jäger
Zsolt Nagy
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Considerations for tisagenlecleucel dosing rationale
Author
Awasthi Rakesh
Baruchel Andre
+17 more
Bishop Michael Russell
Borchmann Peter
Boyer Michael W.
Bubuteishvili-Pacaud Lida
Cota Mariana
Hamilton Jason
Jager Ulrich
Jaglowski Samantha Mary
McGuirk Joseph
Mueller Karen Thudium
Myers Gary Douglas
Rives Susana
Stefanski Heather E.
Tam Constantine Si Lun
Waldron Edward K.
Waller Edmund K.
Yanik Gregory A.
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2018
Field of study
No full text
Kölner UniversitätsPublikationsServer
Considerations for tisagenlecleucel dosing rationale.
Author
Andre Baruchel
Constantine Si Lun Tam
+17 more
Edmund K. Waller
Edward K Waldron
Gary Douglas Myers
Gregory A. Yanik
Heather E Stefanski
Jason Hamilton
Joseph McGuirk
Karen Thudium Mueller
Lida Bubuteishvili-Pacaud
Mariana Cota
Michael Russell Bishop
Michael W. Boyer
Peter Borchmann
Rakesh Awasthi
Samantha Mary Jaglowski
Susana Rives
Ulrich Jäger
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
Author
Constantine Si Lun Tam
Edmund K. Waller
+18 more
Edward K Waldron
Gary Douglas Myers
John E. Levine
Karen Thudium Mueller
Keith Jason August
Lida Bubuteishvili-Pacaud
Mariana Cota
Michael Pulsipher
Michael W. Boyer
Peter Borchmann
Rakesh Awasthi
Ronan Foley
Shannon L. Maude
Stephan A. Grupp
Stephen J. Schuster
Tanya Taran
Theodore Willis Laetsch
Ulrich Jäger
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref